Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
41 hedge funds and large institutions have $426M invested in Prometheus Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$76.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$68.4M |
| 3 |
RI
RTW Investments
New York
|
+$67.4M |
| 4 |
CA
CHI Advisors
New York
|
+$59.3M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$43.3M |
Top Sellers
RXDX Hedge Fund Activity: Q1 2021 in Review
41 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q1 2021, worth a combined $426M.
Buyers outnumbered sellers: 41 funds opened new RXDX positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $76.7M.
- 41 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $426M of Prometheus Biosciences, Inc. Common Stock stock for Q1 2021.
- 41 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +41 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q1 2021 was Eventide Asset Management, an estimated $76.7M added.
Based on aggregated 13F filings for Q1 2021.